Literature DB >> 33881502

Primary resistance to CD19-directed chimeric antigen receptor T-cell therapy in T-cell/histiocyte-rich large B-cell lymphoma.

Jonathan A Trujillo1, James Godfrey1,2, Yifei Hu3,4, Jun Huang4, Sonali M Smith1, Matthew J Frigault5,6, Zachariah DeFilipp5,7, Daniel Appelbaum8, Yonglin Pu8, Nicholas Feinberg8, Thomas Althaus1,9, Michael R Bishop1,9, Peter A Riedell1,9, Justin Kline1,9.   

Abstract

Entities:  

Year:  2021        PMID: 33881502      PMCID: PMC8212512          DOI: 10.1182/blood.2020009148

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


× No keyword cloud information.
  10 in total

1.  Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma.

Authors:  Stephen J Schuster; Michael R Bishop; Constantine S Tam; Edmund K Waller; Peter Borchmann; Joseph P McGuirk; Ulrich Jäger; Samantha Jaglowski; Charalambos Andreadis; Jason R Westin; Isabelle Fleury; Veronika Bachanova; S Ronan Foley; P Joy Ho; Stephan Mielke; John M Magenau; Harald Holte; Serafino Pantano; Lida B Pacaud; Rakesh Awasthi; Jufen Chu; Özlem Anak; Gilles Salles; Richard T Maziarz
Journal:  N Engl J Med       Date:  2018-12-01       Impact factor: 91.245

2.  T-cell/histiocyte-rich large B-cell lymphoma.

Authors:  Stefania Pittaluga; Elaine S Jaffe
Journal:  Haematologica       Date:  2010-03       Impact factor: 9.941

3.  Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial.

Authors:  Frederick L Locke; Armin Ghobadi; Caron A Jacobson; David B Miklos; Lazaros J Lekakis; Olalekan O Oluwole; Yi Lin; Ira Braunschweig; Brian T Hill; John M Timmerman; Abhinav Deol; Patrick M Reagan; Patrick Stiff; Ian W Flinn; Umar Farooq; Andre Goy; Peter A McSweeney; Javier Munoz; Tanya Siddiqi; Julio C Chavez; Alex F Herrera; Nancy L Bartlett; Jeffrey S Wiezorek; Lynn Navale; Allen Xue; Yizhou Jiang; Adrian Bot; John M Rossi; Jenny J Kim; William Y Go; Sattva S Neelapu
Journal:  Lancet Oncol       Date:  2018-12-02       Impact factor: 41.316

4.  Clinical features and survival of patients with T-cell/histiocyte-rich large B-cell lymphoma: analysis of the National Cancer Data Base.

Authors:  Thomas A Ollila; John L Reagan; Adam J Olszewski
Journal:  Leuk Lymphoma       Date:  2019-07-09

5.  High metabolic tumor volume is associated with decreased efficacy of axicabtagene ciloleucel in large B-cell lymphoma.

Authors:  Erin A Dean; Rahul S Mhaskar; Hong Lu; Mina S Mousa; Gabriel S Krivenko; Aleksandr Lazaryan; Christina A Bachmeier; Julio C Chavez; Taiga Nishihori; Marco L Davila; Farhad Khimani; Hien D Liu; Javier Pinilla-Ibarz; Bijal D Shah; Michael D Jain; Yoganand Balagurunathan; Frederick L Locke
Journal:  Blood Adv       Date:  2020-07-28

6.  PD-L1 gene alterations identify a subset of diffuse large B-cell lymphoma harboring a T-cell-inflamed phenotype.

Authors:  James Godfrey; Sravya Tumuluru; Riyue Bao; Michael Leukam; Girish Venkataraman; John Phillip; Carrie Fitzpatrick; James McElherne; Brendan W MacNabb; Robert Orlowski; Sonali M Smith; Justin Kline
Journal:  Blood       Date:  2019-03-25       Impact factor: 22.113

Review 7.  The immune landscape and response to immune checkpoint blockade therapy in lymphoma.

Authors:  Justin Kline; James Godfrey; Stephen M Ansell
Journal:  Blood       Date:  2020-02-20       Impact factor: 22.113

Review 8.  ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells.

Authors:  Daniel W Lee; Bianca D Santomasso; Frederick L Locke; Armin Ghobadi; Cameron J Turtle; Jennifer N Brudno; Marcela V Maus; Jae H Park; Elena Mead; Steven Pavletic; William Y Go; Lamis Eldjerou; Rebecca A Gardner; Noelle Frey; Kevin J Curran; Karl Peggs; Marcelo Pasquini; John F DiPersio; Marcel R M van den Brink; Krishna V Komanduri; Stephan A Grupp; Sattva S Neelapu
Journal:  Biol Blood Marrow Transplant       Date:  2018-12-25       Impact factor: 5.742

9.  JUNB, DUSP2, SGK1, SOCS1 and CREBBP are frequently mutated in T-cell/histiocyte-rich large B-cell lymphoma.

Authors:  Bianca Schuhmacher; Julia Bein; Tobias Rausch; Vladimir Benes; Thomas Tousseyn; Martine Vornanen; Maurilio Ponzoni; Lorenz Thurner; Randy Gascoyne; Christian Steidl; Ralf Küppers; Martin-Leo Hansmann; Sylvia Hartmann
Journal:  Haematologica       Date:  2018-09-13       Impact factor: 9.941

10.  Spatial signatures identify immune escape via PD-1 as a defining feature of T-cell/histiocyte-rich large B-cell lymphoma.

Authors:  Gabriel K Griffin; Jason L Weirather; Margaretha G M Roemer; Mikel Lipschitz; Alyssa Kelley; Pei-Hsuan Chen; Daniel Gusenleitner; Erin Jeter; Christine Pak; Evisa Gjini; Bjoern Chapuy; Michael H Rosenthal; Jie Xu; Benjamin J Chen; Aliyah R Sohani; Scott B Lovitch; Jeremy S Abramson; Jeffrey J Ishizuka; Austin I Kim; Caron A Jacobson; Ann S LaCasce; Christopher D Fletcher; Donna Neuberg; Gordon J Freeman; F Stephen Hodi; Kyle Wright; Azra H Ligon; Eric D Jacobsen; Philippe Armand; Margaret A Shipp; Scott J Rodig
Journal:  Blood       Date:  2021-03-11       Impact factor: 22.113

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.